Regimen | VA Change (LogMAR) at 12 Months | Literature Reference | |||
---|---|---|---|---|---|
From Baseline | Versus Control Group | ||||
This Study | Literature | This Studya | Literature | ||
No Treatment | 0.54 | 0.2 to 0.4 | – | – | |
PDT | 0.48 | 0.2 to 0.3 | −0.06 | −0.14 | |
Bevacizumab | 0.09 | − 0.1 to −0.16 | −0.45 | −0.33b | |
Ranibizumab | 0.07 | −0.1 to −0.2 | −0.47 | −0.35 to −0.41 | |
 PIER study |  | 0.04 |  |  | [11] |
 SAILOR study |  | −0.04 |  |  | [12] |
Anti-VEGF outcome studies |  | −0.1 to −0.02 |  |  |